(Q36099468)

12 August 2017

1 reference

title

The role of reverse genetics in the development of vaccines against respiratory viruses (English)

1 reference

12 August 2017

Marsh GA

1

1 reference

12 August 2017

Tannock GA

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 March 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

5

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

369-380

1 reference

A community-based study of respiratory episodes in Melbourne, Australia

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Epidemiology of respiratory infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Respiratory tract infections as a public health challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Acute respiratory infections in children: a community-based longitudinal study in rural Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Differential response of ferrets to infection with virulent and avirulent influenza viruses: a possible marker of virus attenuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Development and characterization of cold-adapted viruses for use as live virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Co-chairman's remarks: reverse genetics: directed modification of DNA for functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Cloned Poliovirus Complementary DNA Is Infectious in Mammalian Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Qβ DNA-containing hybrid plasmids giving rise to Qβ phage formation in the bacterial host

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Requirements and functions of vesicular stomatitis virus L and NS proteins in the transcription process in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Generation of influenza A viruses entirely from cloned cDNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for va

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Plasmid-only rescue of influenza A virus vaccine candidates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Rescue of influenza B virus from eight plasmids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Recovery of human metapneumovirus genetic lineages a and B from cloned cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Method for introducing site-specific mutations into adenovirus 2 genome: construction of a small deletion mutant in VA-RNAI gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

A DNA transfection system for generation of influenza A virus from eight plasmids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Influenza vaccines: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Influenza A virus with defective M2 ion channel activity as a live vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Eight-plasmid system for rapid generation of influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

The annual production cycle for influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

The role of cell culture vaccines in the control of the next influenza pandemic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Humoral and cell-mediated immunity to vero cell-derived influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Are we ready for pandemic influenza?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Characterization of avian H5N1 influenza viruses from poultry in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Respiratory syncytial virus: reverse genetics and vaccine strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Protection of cotton rats by immunization with the human parainfluenza virus type 3 fusion (F) glycoprotein expressed on the surface of insect cells infected with a recombinant baculovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.3.369

Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization

21 January 2018

1 reference

12 December 2020

Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus.

1 reference

12 December 2020

In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14.

1 reference

12 December 2020

Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus

1 reference

12 December 2020

Infectious rabies viruses from cloned cDNA.

1 reference

12 December 2020

Recovery of infectious human parainfluenza virus type 3 from cDNA.

1 reference

12 December 2020

Future influenza vaccines and the use of genetic recombinants

1 reference

12 December 2020

Respiratory syncytial virus vaccines

1 reference

12 December 2020

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach

1 reference

12 December 2020

An infectious clone of human parainfluenza virus type 3

1 reference

12 December 2020

Alternative base pairs attenuate influenza A virus when introduced into the duplex region of the conserved viral RNA promoter of either the NS or the PA gene.

1 reference

12 December 2020

Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabies-exposed patients in China

1 reference

12 December 2020

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants

1 reference

12 December 2020

Function and structure of RNA polymerase from vesicular stomatitis virus

1 reference

12 December 2020

Magnitude of acute respiratory infections in under five children

1 reference

12 December 2020

Recovery of cytopathogenic agent from chimpanzees with coryza

1 reference

12 December 2020

Viruses and bacteria in the etiology of the common cold

1 reference

12 December 2020

Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.

1 reference

12 December 2020

The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine

1 reference

12 December 2020

Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.

1 reference

12 December 2020

Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge

1 reference

12 December 2020

Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries?

1 reference

12 December 2020

Current use and future directions of adenovirus vaccine

1 reference

12 December 2020

The SARS coronavirus: rapid diagnostics in the limelight

1 reference

12 December 2020

Development of a Vero cell-derived influenza whole virus vaccine.

1 reference

12 December 2020

Plasmid-driven formation of influenza virus-like particles

1 reference

12 December 2020

Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier

1 reference

12 December 2020

Recombinant human respiratory syncytial virus (RSV) from cDNA and construction of subgroup A and B chimeric RSV.

1 reference

12 December 2020

Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route.

1 reference

12 December 2020

Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus

1 reference

12 December 2020

A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to

1 reference

12 December 2020

Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine

1 reference

12 December 2020

Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein

1 reference

12 December 2020

Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong

1 reference

12 December 2020

Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics

1 reference

12 December 2020

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

1 reference

12 December 2020

"Ambisense" approach for the generation of influenza A virus: vRNA and mRNA synthesis from one template

1 reference

12 December 2020

Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles.

1 reference

12 December 2020

Immunopathogenesis of vaccine-enhanced RSV disease.

1 reference

12 December 2020

Rescue of influenza A virus from recombinant DNA.

1 reference

12 December 2020

Improvement of inactivated influenza virus vaccines

1 reference

12 December 2020

Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents

1 reference

12 December 2020

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

1 reference

12 December 2020

Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus

1 reference

12 December 2020

Identifiers

DOI

10.1517/14712598.5.3.369

1 reference

12 August 2017

1 reference